New Evidence Supporting Cyclosporine Efficacy in Epidermal Necrolysis
- PMID: 28941473
- DOI: 10.1016/j.jid.2017.07.828
New Evidence Supporting Cyclosporine Efficacy in Epidermal Necrolysis
Abstract
Sixty years after its original description by Sir Alan Lyell, epidermal necrolysis (from Stevens-Johnson syndrome to toxic epidermal necrolysis) seems finally amenable to a specific treatment in addition to essential symptomatic measures in specialized settings. A recently published systematic review and an article by Gonzales-Herrada et al. strongly suggest that cyclosporine is effective in reducing the risk of death.
Copyright © 2017 The Authors. Published by Elsevier Inc. All rights reserved.
Comment on
-
Cyclosporine Use in Epidermal Necrolysis Is Associated with an Important Mortality Reduction: Evidence from Three Different Approaches.J Invest Dermatol. 2017 Oct;137(10):2092-2100. doi: 10.1016/j.jid.2017.05.022. Epub 2017 Jun 17. J Invest Dermatol. 2017. PMID: 28634032 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
